Learn More-External Link
Trending at Lumira Ventures
Cardiac Dimensions Wins European Clearance to Sell Device for Heart Failure
Learn More-External Link
Cardiac Dimensions(R) Inc. Announces Achievement of Implant Target for TITAN(TM) Safety Study
Learn More-External Link
Cardiac Dimensions® Inc. Receives 2008 Best of Kirkland Award
Learn More-External Link
Cardiac Dimensions(R) Inc. Announces New Vice President of Research & Development
Learn More-External Link
Cardiac Dimensions® Inc. Announces New Vice President of Research & Development
Learn More-External Link
Cardiac Dimensions(R) Inc. Receives ISO 13485:2003 Certification
Learn More-External Link
Cardiac Dimensions® Inc. announces Key Personnel Changes
Learn More-External Link
Cardiac Dimensions(R) Inc. Announces First Implant Of CARILLON(TM) Device In Its TITAN(TM) Study
Learn More-External Link
Cardiac Dimensions® Inc. Announces Completion of European AMAEDUS™ Study
Published: Oct 02, 2007 KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions® Inc., a developer of devices to treat heart failure and related conditions, today announced that it has completed enrollment in the AMADEUS™ trial. AMADEUS™ (Carillon Mitral Annuloplasty Device European Union Study), a …
Cardiac Dimensions® Inc. Announces Closing of $35.5 Million Round of Financing. JJDC & Lumira Capital Co-Lead Round, Providing Funds to Be Used to Support FDA Clinical Trials of the CARILLON™ Mitral Contour System™
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, Inc. announced today it has closed $35.5 million in new venture capital. This Series D financing was co-led by Johnson & Johnson Development Corp. (JJDC) and Lumira Capital, and included Mitsubishi UFJ Capital, West River Capital, …